Serum carbohydrate antigen elevations in endometrial adenocarcinomas: Characterization of DU-PAN-2 expression as a tumor marker

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 1, 2004, Pages 59-64

  Yasuda, Masanori ^a   Saito, Kaoru ^b   Kobayashi, Youichi ^b   Muramatsu, Toshinari ^a   Miyamoto, Tsuyoshi ^a   Murakami, Masaru ^a   Shinozuka, Takao ^a   Ishizuka, Bunpei ^b   Makino, Tsunehisa ^a   Kajiwara, Hiroshi ^a   Osamura, Robert Yoshiyuki ^a  

^a TOKAI UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbohydrate antigen; DU PAN 2; Endometrial adenocarcinoma; Serum marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOHYDRATE ANTIGEN; DUPAN 2; SIALYL LEWIS X ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT MONITORING; PREOPERATIVE EVALUATION; PROTEIN EXPRESSION; SERODIAGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-125 ANTIGEN; CA-19-9 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OLIGOSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 12144288640     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1341-8076.2004.00157.x     Document Type: Article

References (18)

1. Muramatsu T, Yasuda M, Osamura RY et al. Clinicopathological analysis of DU-PAN-2 as a tumor marker for endometrial adenocarcinoma in comparison with CA19-9. Acta Histochem Cytochem 2002; 35: 193-199.
2. a in normal uterine glands. AIMM 1999; 7: 116-121.
3. Muramatsu T, Yasuda M, Itoh J et al. Immunohistochemical characterization of DU-PAN-2 expression in endometrial adenocarcinomas associated with CA19-9 expression. AIMM 1999; 7: 173-180.
4. Kamoshida S, Ogane N, Yasuda M et al. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: The significance for papillary carcinomas. Mod Pathol 2000; 13: 736-741.
5. Kamoshida S, Satoh Y, Yasuda M, Kajiwara H, Tsukinoki K, Osamura RY. Immunohistochemical heterogeneity of type 1 blood group antigen expressions in testicular germ cell tumors. Oncol Reports 2002; 9: 845-851.
6. Kawa S, Oguchi H, Kobayashi T et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991; 64: 899-902.
7. Narimatsu H, Iwasaki H, Nakayama F et al. Lewis and secretor gene dosages affect CA19-9 an DU-PAN-s serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58: 512-518.
8. x in breast cancer.] J Tokyo Wom Med Coll 1993; 63: 1008-1024 (In Japanese with English abstract.)
9. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887.
10. Takada A, Ohmori K, Takahashi N et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl A. Biochem. Biophys Res Comun 1991; 179: 713-719.
11. Takada A, Ohomori K, Yoneda T et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993; 53: 354-361.
12. Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 1997; 66: 238-243.
13. x-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res 1986; 46: 2627-2632.
14. Inoue M, Nakayama M, Tanizawa O. Altered expression of Lewis blood group and related antigens in fetal, normal adult and malignant tissues of the uterine endometrium. Virchows Arch a Pathol Anat 1990; 416: 221-228.
15. Twanari O, Miyako J, Date Y et al. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest 1990; 29: 214-218.
16. Nitoff IM, Klug T, Schaetzl E, Zurawski R, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984; 148: 1057-1058.
17. Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA125 levels in clinically localized and advanced endometrial carcioma. Am J Obstet Gynecol 1988; 158: 399-402.
18. Duk JM, Aalders JG, Fleuren GJ, de Bruijin HWA. CA125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986; 155: 1097-1102.